|
pubmed:abstractText |
It has been clarified that visceral fat accumulation leads to atherosclerosis through multiple risk factors such as insulin resistance, glucose intolerance, hyperlipidemia and hypertension. So far, it has been reported that a thaizolidinedione derivative, troglitazone, improves the insulin resistance in subjects with diabetes, glucose intolerance and obesity. However, it has not been reported yet that troglitazone affects fat distribution in subjects concomitant with visceral fat accumulation and multiple risk factors.
|
|
pubmed:affiliation |
Department of Internal Medicine and Molecular Science, Graduate School of Medicine Osaka University, 2-2 Yamadaoka, Suita, 565-0871 Osaka, Japan. tadashi@imed2.med.osaka-u.ac.jp
|
